ClinicalTrials.gg

Neuroblastoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 676 studies for Neuroblastoma across more than 10 countries. 128 are recruiting or about to start. 394 of them are mainly about Neuroblastoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Esthesioneuroblastoma, Olfactory: 751 studies, 132 open.

ClinicalTrials.gov finds 772 studies for Neuroblastoma. How that becomes 675 here

This page counts the studies the registry files under Neuroblastoma, and those it files under no condition that list Neuroblastomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 772Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −75Filed under a narrower condition, counted on its own pageEsthesioneuroblastoma, Olfactory 72 · Ganglioneuroblastoma 2
  3. −11List Neuroblastoma as a condition, but the registry did not file them under itMost often written as “Disseminated Neuroblastoma” (3), “Localized Resectable Neuroblastoma” (1), and “Neuroblastoma. CNS” (1). The registry filed them under other conditions only, most often Recurrence (5) and Pdgfra-Associated Chronic Eosinophilic Leukemia (3).
  4. −11Match it another way7 name it in the title and 4 in a keyword.
  5. 675The count on this page22 of them list Neuroblastoma in their own words; the registry filed them under no condition.

Status

Completed
339
Recruiting
105
Terminated
66
Active, not recruiting
57
Status unknown
52
Withdrawn
26

Phase

Phase 1
267
Phase 2
256
Phase 3
47
Early Phase 1
16
Phase 4
4

Where

United States
469
Canada
88
France
54
United Kingdom
52
Australia
50
China
42

Who develops what

Add Neuroblastoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
fludarabineRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07502287 · Beijing Biotech · Phase 2 · live · background · “Fludarabine” · registered Mar 2026
  • NCT04029688 · Hoffmann-La Roche · Phase 2 · background · “Fludarabine” · registered Jul 2019
Beijing Biotech18% of its industry studies11 study
CyclophosphamideRecent, limited
Evidence
  • NCT07502287 · Beijing Biotech · Phase 2 · live · background · “Cyclophosphamide” · registered Mar 2026
  • NCT04029688 · Hoffmann-La Roche · Phase 2 · background · “Cyclophosphamide” · registered Jul 2019
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed11 study
Granulocyte-Macrophage Colony-Stimulating FactorEarlier only
Evidence
  • NCT04909515 · Y-mAbs Therapeutics · Phase 2 · background · “GM-CSF” · registered May 2021
  • NCT04238819 · Eli Lilly and Company · Phase 2 · background · “GM-CSF” · registered Jan 2020
  • NCT00969722 · United Therapeutics · Phase 2 · background · “Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)” · registered Aug 2009
Sellas Life Sciences Group18% of its industry studies00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 14 Mar 2027 est.EB-DTNB-NK · Beijing Biotech · Phase 2 named, not the main aimstudied with fludarabinestudied with CyclophosphamideNCT07502287 Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma — primary endpoint: Incidence of dose-limiting toxicities (DLTs) after first CARNK infusion, using protocol-defined DLT criteria. · 36 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Neuroblastoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Alkylating agents 11 open · Tyrosine kinase inhibitors (TKIs) 4 open · Antimitotic agents 3 open · Antimetabolites 2 open · HDAC inhibitors 2 open

Coming up

55studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 105 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 75 (71%) stop at 75 or younger. 102 (97%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (3%) take healthy volunteers.

Recruiting studies that take each age, of 105
AgeWomenMen
10101 (96%)101 (96%)
18100 (95%)100 (95%)
3054 (51%)54 (51%)
4035 (33%)35 (33%)
5033 (31%)33 (31%)
6531 (30%)31 (30%)
7530 (29%)30 (29%)
8529 (28%)29 (28%)

Across all 676 studies, recruiting or not: 70% stop at 75 or younger and 68% at 65; 94% take children; 0% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neuroblastoma studies take

Of 86 phase 1 interventional studies under Neuroblastoma, half reached primary completion within 83 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 183 mo60–114 · 86 studies—89 mo65–117 · 73 studies
Phase 1/280 mo62–115 · 35 studies——
Phase 274 mo52–99 · 67 studies—74 mo52–99 · 62 studies
Phase 396 mo80–122 · 19 studies——
Observational213 mo74–304 · 34 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 676. Browse all 676 → or search them.